News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
325,121 Results
Type
Article (26376)
Company Profile (146)
Press Release (298599)
Multimedia
Podcasts (30)
Webinars (11)
Section
Business (91372)
Career Advice (1309)
Deals (14168)
Drug Delivery (80)
Drug Development (38324)
Employer Resources (155)
FDA (7994)
Job Trends (8563)
News (153478)
Policy (13472)
Tag
Academia (1971)
Academic (2)
Accelerated approval (3)
Adcomms (17)
Allergies (76)
Alliances (25258)
ALS (70)
Alzheimer's disease (854)
Antibody-drug conjugate (ADC) (75)
Approvals (8030)
Artificial intelligence (179)
Autoimmune disease (13)
Automation (12)
Bankruptcy (97)
Best Places to Work (7327)
BIOSECURE Act (13)
Biosimilars (67)
Biotechnology (90)
Bladder cancer (56)
Brain cancer (17)
Breast cancer (165)
Cancer (1225)
Cardiovascular disease (107)
Career advice (1154)
Career pathing (33)
CAR-T (91)
Cell therapy (260)
Cervical cancer (13)
Clinical research (31322)
Collaboration (545)
Compensation (211)
Complete response letters (12)
COVID-19 (1323)
CRISPR (31)
C-suite (178)
Cystic fibrosis (82)
Data (1445)
Decentralized trials (1)
Denatured (21)
Depression (29)
Diabetes (165)
Diagnostics (3359)
Digital health (7)
Diversity (7)
Diversity, equity & inclusion (39)
Drug discovery (72)
Drug pricing (61)
Drug shortages (5)
Duchenne muscular dystrophy (64)
Earnings (26707)
Editorial (18)
Employer branding (24)
Employer resources (134)
Events (49334)
Executive appointments (532)
FDA (8877)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (510)
Gene editing (73)
Generative AI (16)
Gene therapy (216)
GLP-1 (395)
Government (2293)
Grass and pollen (2)
Guidances (78)
Healthcare (9852)
Huntington's disease (16)
IgA nephropathy (20)
Immunology and inflammation (49)
Indications (16)
Infectious disease (1410)
Inflammatory bowel disease (107)
Inflation Reduction Act (8)
Influenza (27)
Intellectual property (52)
Interviews (196)
IPO (6382)
IRA (23)
Job creations (1571)
Job search strategy (1006)
Kidney cancer (2)
Labor market (39)
Layoffs (191)
Leadership (16)
Legal (2171)
Liver cancer (42)
Lung cancer (168)
Lymphoma (94)
Machine learning (4)
Management (52)
Manufacturing (185)
MASH (31)
Medical device (6295)
Medtech (6299)
Mergers & acquisitions (8157)
Metabolic disorders (384)
Multiple sclerosis (52)
NASH (11)
Neurodegenerative disease (46)
Neuropsychiatric disorders (7)
Neuroscience (1216)
NextGen: Class of 2025 (3664)
Non-profit (3456)
Now hiring (39)
Obesity (191)
Opinion (129)
Ovarian cancer (47)
Pain (58)
Pancreatic cancer (44)
Parkinson's disease (102)
Partnered (14)
Patents (111)
Patient recruitment (67)
Peanut (42)
People (33665)
Pharmaceutical (41)
Pharmacy benefit managers (4)
Phase I (9034)
Phase II (13519)
Phase III (11614)
Pipeline (733)
Policy (70)
Postmarket research (1238)
Preclinical (3964)
Press Release (61)
Prostate cancer (61)
Psychedelics (18)
Radiopharmaceuticals (120)
Rare diseases (281)
Real estate (3199)
Recruiting (59)
Regulatory (10200)
Reports (42)
Research institute (1728)
Resumes & cover letters (165)
Rett syndrome (5)
RNA editing (2)
RSV (32)
Schizophrenia (48)
Series A (94)
Series B (57)
Service/supplier (8)
Sickle cell disease (40)
Special edition (8)
Spinal muscular atrophy (108)
Sponsored (24)
Startups (2370)
State (1)
Stomach cancer (8)
Supply chain (29)
Tariffs (11)
The Weekly (9)
Vaccines (324)
Venture capitalists (32)
Weight loss (117)
Women's health (16)
Worklife (18)
Date
Last 7 days (519)
Last 30 days (1674)
Last 365 days (18496)
2025 (6742)
2024 (20047)
2023 (22460)
2022 (27552)
2021 (30632)
2020 (28324)
2019 (25198)
2018 (18731)
2017 (16363)
2016 (15825)
2015 (17415)
2014 (12650)
2013 (10239)
2012 (10756)
2011 (11092)
2010 (10054)
Location
Africa (477)
Alabama (30)
Alaska (7)
Arizona (100)
Arkansas (9)
Asia (18697)
Australia (3395)
California (3529)
Canada (1036)
China (247)
Colorado (137)
Connecticut (175)
Delaware (119)
Europe (46596)
Florida (561)
Georgia (138)
Hawaii (1)
Idaho (23)
Illinois (283)
India (22)
Indiana (261)
Iowa (8)
Japan (138)
Kansas (47)
Kentucky (15)
Louisiana (8)
Maine (14)
Maryland (469)
Massachusetts (2712)
Michigan (130)
Minnesota (209)
Mississippi (2)
Missouri (45)
Montana (17)
Nebraska (10)
Nevada (43)
New Hampshire (18)
New Jersey (1119)
New Mexico (19)
New York (1046)
North Carolina (645)
North Dakota (8)
Northern California (1584)
Ohio (132)
Oklahoma (7)
Oregon (22)
Pennsylvania (759)
Puerto Rico (9)
Rhode Island (16)
South America (627)
South Carolina (10)
Southern California (1282)
Tennessee (43)
Texas (448)
United States (13400)
Utah (87)
Virginia (73)
Washington D.C. (43)
Washington State (238)
West Virginia (1)
Wisconsin (49)
325,121 Results for "endra life sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies
March 31, 2025
·
7 min read
BioMidwest
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering
ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company.
June 4, 2024
·
6 min read
BioMidwest
ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, announces the issuance of five new patents, including three in Europe and two in China.
May 2, 2024
·
5 min read
Press Releases
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
November 22, 2024
·
3 min read
Business
ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months ended March 31, 2024 on Tuesday, May 14, 2024 after the close of trading on the U.S. financial markets.
May 7, 2024
·
2 min read
Business
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2024 and provided a business update.
May 14, 2024
·
10 min read
Business
New Jersey’s Life Sciences Scene Continues Expanding Beyond Big Pharma
Known as the home of big-name companies including Johnson & Johnson, New Jersey has become a destination for more and more small and midsize life sciences businesses. Choose New Jersey, Grace Therapeutics and Onyx Equities executives discuss the state’s life sciences scene.
April 10, 2025
·
6 min read
·
Angela Gabriel
Press Releases
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
November 15, 2024
·
10 min read
Job Trends
Report: 2025 U.S. Life Sciences Salary Report
March 25, 2025
·
1 min read
·
BioSpace Insights
Business
ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024
ENDRA Life Sciences Inc. today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets.
March 21, 2024
·
2 min read
1 of 32,513
Next
